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We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral virG Shigella sonnei vaccine
candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose
of either placebo (n  7) or vaccine (n  27) at 3  103 CFU (group 1), 3  104 CFU (group 2), 3  105 CFU
(group 3), or 3  106 CFU (group 4). The vaccine was generally well tolerated, although a low-grade fever or
mild diarrhea occurred in six (22%) of the vaccine recipients. WRSS1 was recovered from the stools of 50 to
100% of the vaccinees in each group. The geometric mean peak anti-lipopolysaccharide responses in groups 1
to 4, respectively, were 99, 39, 278, and 233 for immunoglobulin (IgA) antibody-secreting cell counts; 401, 201,
533, and 284 for serum reciprocal IgG titers; and 25, 3, 489, and 1,092 for fecal IgA reciprocal titers. Post-
vaccination increases in gamma interferon production in response to Shigella antigens occurred in some
volunteers. We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 103 to 106
CFU but elicits clinical reactions that must be assessed in further volunteer trials.
Shigella infection causes considerable morbidity and mortal-
ity, mostly among young children living in developing countries
(14). Development of a safe and effective vaccine could pro-
vide a valuable tool for controlling this recalcitrant disease. To
make an impact globally, a vaccine must protect against the
three serogroups responsible for most of the disease. In devel-
oping countries, Shigella dysenteriae type 1 causes epidemic and
pandemic dysentery and S. flexneri (15 serotypes) is the most
common agent of endemic disease, with a small (10%) (14)
but clinically important (9) contribution from S. sonnei. S.
sonnei is the main serogroup found in industrialized countries,
where it causes approximately 70% of both endemic and trav-
el-related cases of shigellosis (14).
One strategy for developing a multivalent Shigella vaccine is
to construct a series of strains in which the fundamental mu-
tation is a deletion in plasmid-located virG (also known as
icsA). The product of virG is required for intercellular spread
of Shigella within the intestinal epithelium (1, 15). Sansonetti
and colleagues attenuated S. flexneri 2a by creating deletions in
virG and iuc (25) (a chromosomal gene encoding the sid-
erophore aerobactin). In volunteers, a single oral 104-CFU
dose of this strain, designated SC602, was generally safe (al-
though mild fever or diarrhea developed in 5 to 8% of the
subjects) and immunogenic and elicited significant protection
against a wild-type challenge (4). In the rabbit ileal-loop assay,
the deletion in iuc produced little additional attenuation over
that provided by mutated virG alone (25), prompting construc-
tion of additional Shigella vaccine strains attenuated solely on
the basis of virG. In pursuit of this strategy, we performed a
phase I evaluation of WRSS1, a live oral S. sonnei vaccine
candidate that Hartman and Venkatesan have attenuated by a
deletion within virG (7).
MATERIALS AND METHODS
Vaccine. WRSS1 was constructed from the Mosely strain of S. sonnei as
previously described (7). In brief, a parent strain was selected that exhibited
stability of the form I (smooth) colonial phenotype. This screening process
represented an attempt to overcome the predilection of S. sonnei strains to
spontaneously lose the virulence plasmid, which bears the genes associated with
invasion of epithelial cells, as well as the genes encoding the O antigen. sacB
suicide vector pCVD422 was used to replace the wild-type virG allele with virG
possessing a 212-bp deletion. In preclinical experiments, WRSS1 exhibited
95% form I colonies after overnight growth, did not produce keratoconjunc-
tivitis in guinea pigs (Sereny test), and did not form plaques on cultured epithe-
lial cells (indicating absence of cell-to-cell spread) but retained its invasiveness
phenotype. In the guinea pig Sereny challenge model, WRSS1 was both immu-
nogenic and protective (7).
WRSS1 was manufactured at the Walter Reed Army Institute of Research
Pilot Bioproduction Facility in Forest Glen, Md. The final composition (3.7 
1010 CFU of WRSS1 per ml in phosphate buffer saline containing 7.5% dextran
T10, 2% sucrose, and 1.5% glycerol as a cryopreservative) was lyophilized,
dispensed into vials, and stored at 70°C until use.
Subjects. Healthy community volunteers 18 to 45 years old were recruited as
previously described (12). Informed consent was obtained in accordance with the
guidelines of the University of Maryland, Baltimore Institutional Review Board,
the Surgeon General’s Human Subjects Research Review Board, and the Human
Use Review Committee of the Walter Reed Army Institute of Research.
Study design. Two randomized, double-blind, placebo-controlled trials were
conducted in the Inpatient Research Isolation Ward of the Center for Vaccine
Development. In the first trial, three vaccine inocula (3  103, 3  104, and 3 
105 CFU) were evaluated sequentially in a placebo-controlled fashion. In the
second trial, volunteers were randomly assigned to receive either the vaccine (3
 105 or 3  106 CFU) or a placebo. The groups that received 3  105 CFU in
the first and second trials were combined for analysis (Table 1). The vaccine and
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placebo were prepared by unblinded study personnel who did not participate in
the clinical care or assessment of volunteers.
Inoculation and clinical evaluation. Fasting volunteers ingested 2 g of sodium
bicarbonate buffer dissolved in 150 ml of water, followed 1 min later by 30 ml of
water containing the assigned vaccine dose or no vaccine (placebo). A physician
queried each subject daily about the occurrence of anorexia, malaise, abdominal
cramps, or headache. Volunteers graded the severity of their headaches and
cramps as follows: 1, scarcely or easily noticed symptom but continued normal
activity; 2, could not take mind off symptom but continued normal activity; 3,
went to bed because of symptom but some activity possible; 4, symptom pre-
vented any activity. Clinical events occurring within 6 days of vaccination are
reported herein.
Nurses measured oral temperatures every 8 h. They graded the volunteers’
stools for consistency by using previously published criteria (16), examined each
for blood, and weighed all loose stools (grades 3 to 5) to estimate volume. Six
days after inoculation, subjects received ciprofloxacin orally for 3 days, 500 mg
every 12 h, to eradicate vaccine excretion.
The following clinical reactions were designated illness: diarrhea (two or more
loose stools totaling at least 200 ml in 48 h or a single loose stool totaling at least
300 ml), dysentery (gross blood in a loose stool), or fever (an oral temperature
of at least 100°F measured at two readings 5 min apart).
Bacteriology. Vaccine excretion was detected by culturing all of the stools
passed during inpatient isolation and once weekly for 3 weeks after discharge by
using previously published methods (11). Excretion was quantified for 6 days
after vaccination as previously described (11).
Immune responses. Immunoglobulin A (IgA) antibody-secreting cells (ASC)
circulating in the peripheral blood that recognize S. sonnei lipopolysaccharide
(LPS) and a water-extractable antigen (21) presumed to contain the invasion
plasmid antigens (Ipa) were enumerated (per 106 peripheral blood mononuclear
cells [PBMC]) by ELISPOT before and on days 7 and 10 after vaccination as
previously described (26). Antibodies to the same antigens (LPS and Ipa) were
measured by enzyme-linked immunosorbent assay in serum (IgG and IgA) be-
fore vaccination and on days 7, 14, 21, and 28 postvaccination (2, 21) and in stool
(IgA) before vaccination and on days 3, 7, 10, and 14 postvaccination (12).
Results are expressed as reciprocal titers.
PBMC were isolated from blood drawn before and 28 days after inoculation
and cryopreserved in liquid nitrogen. Proliferative and cytokine responses (gam-
ma interferon [IFN-] and interleukin-10 [IL-10]) to Shigella antigens (purified
recombinant IpaB, IpaC, and IpaD and a WRSS1 homogenate, each at 5 g/ml,
and a particulate WRSS1 preparation at 4  105 particles per well [17, 22, 24])
were measured as previously described (24). Bovine serum albumin (BSA, 5
g/ml) and anti-CD3/anti-CD28 beads (3 l/ml; Dynal Biotech ASA, Oslo,
Norway) were used as negative and positive controls, respectively. Data are
presented as net increases in cytokine production and were calculated by sub-
tracting the preimmunization cytokine levels (in picograms per milliliter) from
postimmunization values for each antigen and volunteer. Sufficient numbers of
PBMC were available for the evaluation of cell-mediated immune responses in
5, 4, 10, and 4 subjects in groups 1, 2, 3, and 4, respectively, and for seven placebo
recipients.
Fecal lactoferrin. Fecal lactoferrin was measured prevaccination, 72 h post-
vaccination, and in the first diarrheal stool (if diarrhea occurred) by latex bead
agglutination to assess whether vaccination elicited an intestinal inflammatory
response (19).
Statistical analysis. Proliferative and cytokine responses of individual subjects
were defined as significant rises in geometric mean levels, as evaluated by one-
sided, paired t tests. Group differences in geometric mean proliferative and
cytokine responses were analyzed by using t tests evaluating two-sided hypoth-
eses. Statistical significance was assessed at the 5% level throughout.
RESULTS
Clinical response. Six volunteers met the definition of illness
that was possibly vaccine related. One (14%) of the subjects in
group 1 developed a fever of 101.2°F on day 3 postvaccination.
He experienced 2 days of cramps (grade 2), headache (grade
3), anorexia, malaise, and myalgias. He passed two loose stools
(totaling 72 ml). Four subjects in group 3 developed illnesses,
of which three (30%) were considered to be vaccine related.
One had a fever (100.7°F) on day 3, the second developed
diarrhea (two loose stools totaling 229 ml) on day 4, and the
third had a fever (100.8°F) on day 2 that was associated with
anorexia, malaise, grade 2 headache, arthralgia, and chest
pains. He passed two loose stools totaling 170 ml. A fourth
volunteer developed a fever (100.4°F) on day 6 that was attrib-
TABLE 1. Immune responses to WRSS1 by inoculum size
Response Placebo(n 	 7)
3  103 CFU
(group 1 [n 	 7])
3  104 CFU
(group 2 [n 	 4])
3  105 CFU
(group 3 [n 	 10])
3  106 CFU
(group 4 [n 	 6])
Anti-LPS
ASCa
IgA 0.2, 3.5 0.4, 98.5 1.2, 38.6 0.1, 277.7 0.2, 233.4
IgG 0.0, 0.5 0.5, 30.4 0.0, 5.2 0.0 27.7 0.2, 58.0
Serum antibodyb
IgA 34 (14) 245 (71) 120 (50) 703 (70) 566 (100)
IgG 56 (43) 401 (86) 201 (50) 533 (70) 284 (83)
Fecal IgA antibodyb 10 (0) 26 (17) 3 (0) 489 (75) 1,092 (100)
Anti-Ipa
ASCa
IgA 0.0, 3.2 0.1, 7.1 0.3, 27.8 0.1, 33.2 0.0, 10.6
IgG 0.0, 0.3 0.3, 4.0 0.0, 26.8 0.0, 5.1 0.0, 4.6
Serum antibodyb
IgA 28 (0) 37 (14) 85 (50) 58 (30) 89 (17)
IgG 489 (14) 298 (0) 951 (25) 284 (40) 226 (0)
Fecal IgA antibodyb 246 (80) 170 (83) 3 (0) 325 (38) 1,092 (25)
a For ASC, the prevaccination and peak postvaccination geometric mean numbers per 106 PBMC are shown. Samples were collected on days 7 and 10 postvacci-
nation; the greater value from each subject was used to calculate the peak postvaccination geometric mean for the dose group.
b For antibodies the geometric mean peak postvaccination reciprocal titer (percentage of subjects with a fourfold or greater rise in titer postvaccination) is shown.
Following vaccination, samples were collected on days 7, 14, 21, and 28 for serum antibody titer measurement and on days 3, 7, 10, and 14 for fecal antibody titer
measurement. The highest postvaccination titer for each subject was used to calculate the peak postvaccination geometric mean for the dose group.
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uted to a dental abscess. Two (33%) of the volunteers in group
4 met the criteria for illness. One had asymptomatic diarrhea
(three loose stools totaling 244 ml) for the first 2 days after
vaccination. The second had three diarrheal stools (totaling
365 ml) and mild (grade 1) cramps for 4 days after vaccination.
No volunteer had dysentery or a high fever (102°F).
Nine vaccinees (33%) reported abdominal cramps, and 8
(30%) had headaches. However, only two subjects reported
that their symptom interfered with normal activity (both were
grade 3 headaches) and no subject reported a grade 4 symp-
tom. These reactions did not occur in placebo recipients and
were not dose related.
Vaccine shedding. WRSS1 was recovered from the stools of
5 (71%), 2 (50%), 9 (90%), and 6 (100%) vaccinees in groups
1, 2, 3, and 4, respectively, but from none of the placebo
recipients who were residing on the ward together with those
excreting vaccine. The respective groupwise geometric mean
excretion peaks were 5.5  104, 2.2  102, 1.3  106, and 7.5
 106 CFU/g of stool. The percentage of subjects who excreted
vaccine organisms (Fig. 1A) and the geometric mean CFU of
vaccine in stool (Fig. 1B) remained relatively constant on each
postvaccination day until antibiotics were administered.
Fecal lactoferrin. Fecal lactoferrin was detected postvacci-
nation only in the volunteer who had developed a dental ab-
scess.
Immune responses. Vaccination elicited vigorous IgA ASC
anti-LPS responses in all of the groups (Table 1). The counts
exceeded 100 in most subjects, except for those in group 2 (Fig.
2A). ASC responses were less common and smaller in magni-
tude in the IgG anti-LPS assay (Table 1) and in both anti-Ipa
assays (Fig. 2B; Table 1).
Geometric mean peak postvaccination anti-LPS serum IgG
and fecal IgA titers were also robust (Table 1). With the
exception of those in group 2, most of the subjects exhibited a
fourfold rise in serum and/or fecal anti-LPS antibody titers
(Table 1). Whereas the anti-LPS IgA ASC and fecal antibody
responses tended to increase with the dose, a similar trend was
not apparent in serum antibody responses. In contrast, re-
sponses to Ipa were inconsistent, with many subjects exhibiting
preexisting antibodies to this antigen (Table 1). Although no
placebo recipient excreted WRSS1, several demonstrated im-
mune responses, albeit of a smaller magnitude compared with
those of vaccine recipients (Table 1; Fig. 2).
FIG. 1. Excretion of vaccine. Panel A shows the percentage of
subjects shedding vaccine on each postinoculation day after receiving
a single oral dose of either 103, 104, 105, or 106 CFU of strain WRSS1.
Stools were inoculated in enrichment broth and plated on enteric
media. Panel B shows the geometric mean number of CFU per gram
of stool on the first 6 postinoculation days in each of the four groups
of volunteers. To quantify excretion, stools were serially diluted and
plated on MacConkey agar.
FIG. 2. Reverse cumulative distribution curves (reference 23) by
vaccine inoculum for ASC responses to S. sonnei LPS and Ipa. Each
curve plots the proportion of vaccine or placebo recipients (ordinate)
whose peak ASC count (per 106 PBMC), measured 7 to 10 days
postinoculation, equals or exceeds the count shown on the abscissa.
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Mean net increases of 80 (range, 80 to 3,628) pg/ml in
postvaccination IFN- production following PBMC exposure
to two or more Shigella antigens were observed in 1 (20%) of
5, 1 (25%) of 4, 5 (50%)of 10, and 2 (50%) of 4 vaccinees in
groups 1, 2, 3, and 4, respectively, and in 3 (43%) of 7 placebo
recipients. These responses were most marked with the two
larger vaccine doses (Fig. 3); however, there were no signifi-
cant intergroup differences. No increases were observed in
response to BSA. Postvaccination antigen-specific proliferative
responses and increases in IL-10 production were not seen.
DISCUSSION
These findings demonstrate that WRSS1 is a remarkably
immunogenic vaccine candidate. Although the precise immune
responses that correlate with protection against shigellosis are
not known, there is evidence that type-specific (anti-LPS) im-
munity is of critical importance. Vaccine-induced protective
immunity that was serotype specific was demonstrated in field
trials evaluating both streptomycin-dependent oral vaccines
(18) and a parenteral S. sonnei O-antigen-specific polysaccha-
ride conjugate vaccine (3). Similarly, homotypic immunity con-
ferred by wild-type infection has been found in animal models
(6), in epidemiologic studies (5), and in volunteer challenge
experiments (8, 11). A response that has been correlated with
protective efficacy in clinical trials is the anti-Shigella LPS IgA
ASC count, which presumably reflects the degree of mucosal
priming induced by an immunogen (10). In the field setting,
preexisting IgA and IgG anti-LPS serum antibodies have been
associated with protection against shigellosis following natural
exposure (D. Cohen, M. S. Green, C. Block, R. Slepon, and Y.
Lerman, Letter, J. Infect. Dis. 165:785–787, 1992). Thus, the
observation that WRSS1 elicits vigorous anti-LPS IgA ASC
and serum IgA and IgG antibody responses that are similar in
magnitude to those elicited by other strains that prevented
illness following experimental challenge (4) suggests that this
vaccine may confer protection.
Furthermore, we have observed that immunization with
WRSS1 elicits IFN- production by PBMC exposed to Shigella
antigens, including highly purified preparations of IpaB, IpaC,
and IpaD. Similar responses have been seen in volunteers who
received other attenuated Shigella strains, including Shiga tox-
in-deficient S. dysenteriae 1 strain SC595 (24) and S. flexneri 2a
strain CVD 1207 (13). However, this is the first time that an
increase in IFN- production in response to IpaB was observed
following immunization with attenuated Shigella strains. These
results suggest that WRSS1 may be capable of eliciting a broad
range of immune responses, including a type 1 cell-mediated
immune response, which is likely to prevent invasion of eu-
karyotic cells and enhance the ability of macrophages to elim-
inate shigellae that gain access to the intracellular compart-
ment (20, 24).
It is notable that some subjects exhibited immune responses
FIG. 3. IFN- production by volunteers following oral immunization with S. sonnei. PBMC obtained from volunteers before immunization and
at 28 days after immunization were evaluated for IFN- production in response to BSA (negative control) or Shigella antigens (IpaB, IpaC, IpaD,
SSh [S. sonnei homogenate], and SSp [S. sonnei particulate]) as described in Materials and Methods. Results are expressed as mean net increases
in IFN- production following immunization and include all of the evaluated volunteers in each group.
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to Shigella antigens following placebo inoculation, raising ques-
tions as to whether WRSS1 may have been transmitted while
the subjects resided in the Isolation Ward. This and other trials
have shown that exposure to very few Shigella organisms (103
CFU) elicits IFN-, serum antibody, and ASC responses (24).
The lack of fecal vaccine excretion and clinical symptoms in
placebo recipients renders the significance of these immuno-
logical observations uncertain. However, culture is a relatively
insensitive technique for identifying WRSS1 in stool (103 CFU
of WRSS1 per g of stool was the minimum count detected
when stool was experimentally inoculated with known quanti-
ties of WRSS1 organisms [unpublished data]). The possibility
of person-to-person transmission of WRSS1 should be care-
fully evaluated in future vaccine trials, for example, by attempt-
ing to detect shigellae in stools by molecular methods.
Decisions about further development of WRSS1 must take
into account the objective clinical reactions (fever and diar-
rhea) observed in six vaccine recipients (22%). These reactions
occurred across the dose range. Although symptoms were gen-
erally mild and brief, phase II studies must be designed to
assess whether such reactions will be acceptable to subjects
who are ambulatory and engaged in normal activities, partic-
ularly if WRSS1 is to be developed for use by travelers and
military personnel. Large, placebo-controlled phase II studies
will also gauge the relevance of the subjective complaints
(headache, abdominal cramps) reported by vaccinees but not
controls.
For reasons that could not be determined, recipients of 3 
104 CFU of WRSS1 (group 2) seemed to have lower anti-LPS
immune responses and diminished vaccine excretion compared
with recipients of other doses. This could not be explained by
an apparent loss of viability. There were no differences in the
time interval from reconstitution to completion of vaccination
or in the percentage of the inoculum that remained viable
following vaccination of group 2 compared with that of the
other groups (data not shown). Furthermore, one subject (a
low responder) was inoculated on a different day than the
other three. Given the small sample sizes, it is quite possible
that, by chance alone, the occasional volunteers who did not
respond to WRSS1 were clustered in group 2.
These data support the findings of previous studies with
virG S. flexneri 2a strain SC602 that suggested that small
doses (105 CFU) of a strain with a single mutation in virG
may be sufficient to attenuate S. flexneri 2a for humans (4). By
blocking the ability of shigellae to spread from cell to cell
within the epithelium, the extent of infection is limited. How-
ever, when expanded clinical trials of SC602 were conducted
among North American volunteers, it became apparent that
larger doses (2  106 or 3  108 CFU) cause shigellosis (fever,
diarrhea, and/or severe intestinal or constitutional symptoms)
in the majority of subjects, illustrating the delicate balance
between reactogenicity and immunogenicity that has chal-
lenged live, attenuated Shigella vaccine development (4). Most
previous live Shigella vaccine constructs were developed by
using an alternative strategy of creating multiple disabling mu-
tations and then administering large doses of vaccine (ca. 108
to 109 CFU) (12, 13). While these highly attenuated constructs
offer the potential for a greater margin of safety and further
diminish the minimal risk of reversion by recombination, their
immunogenicity has been lower compared with that of WRSS1.
We conclude that a single oral dose of WRSS1 in the range
of 3  103 to 3  106 CFU is remarkably immunogenic,
eliciting vigorous immune responses that generally appear to
increase with vaccine inoculum size in assays that have been
correlated with protection against shigellosis (anti-LPS IgA
ASC and serum anti-LPS IgG). However, clinical reactions,
including mild diarrhea, low-grade fever, headache, and ab-
dominal cramps, occur in 22 to 33% of recipients. The clinical
acceptability of this vaccine will be addressed in future trials
among ambulatory subjects from areas where shigellosis is
endemic and from areas where it is not endemic.
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